Celularity Inc. (CELU) AI Stock Analysis

Celularity Inc. is a clinical-stage biotechnology company based in Florham Park, New Jersey, focusing on off-the-shelf placental-derived allogeneic cell therapies. It operates across three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its clinical pipeline features CYCART-19 targeting B-cell malignancies, CYNK-001 for acute myeloid leukemia, glioblastoma multiforme, and COVID-19, as well as CYNK-101 for HER2+ gastric and gastroesophageal cancers. In pre-clinical development, the company is advancing APPL-001 and PDA-002. Beyond cell therapies, Celularity markets surgical and wound care products, including Biovance and Interfyl, and provides stem cell storage through its LifebankUSA BioBanking division.

Revenue grew from $21.3M in FY2021 to $54.2M in FY2024 before dropping 51.0% to $26.6M in FY2025. Over the 5-year period from FY2020 to FY2025, revenue delivered a CAGR of 13.2%. Gross margin improved to 76.0% in FY2025 from 72.4% in FY2024 and -9.4% in FY2022. Operating margin remained negative at -230.9% in FY2025, while net loss expanded to -$91.8M compared to -$57.9M in FY2024. For the trailing twelve months, revenue was $19.0M with an operating margin of -263.5% and an eps of -$2.52. For the latest quarter ended June 30, 2026, quarterly revenue fell 66.3% year-over-year, while quarterly earnings declined 61.3%.

As of June 30, 2026, Celularity held $368,000 in cash and short-term investments against $60.3M in total debt, resulting in net debt of $59.9M. The company had total assets of $99.5M, a current ratio of 0.09, and negative shareholders' equity of -$35.3M. In FY2025, operating cash flow was -$13.3M and free cash flow was -$13.3M. Over five years, the company expanded its share count by 144.1%, while paying $5.9M in dividends during FY2025.

Celularity trades at a price-to-sales multiple of 2.1x and an EV to revenue multiple of 2.6x, compared to a median price-to-sales of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 9.9x. The company has an enterprise value of $68.3M and a market cap of $40.6M. Over the past year, CELU shares fell 41.3%, while the S&P 500 gained 16.8%. Over a 5-year timeframe, the stock declined 98.3%, compared to an 83.0% gain for the S&P 500. Shares closed at $1.25 on October 16, 2026, which is 13.5% above the 200-day average.

Wall Street coverage includes a mean price target of $2.50 for Celularity, representing 100.0% upside compared to its last close of $1.25 on October 16, 2026. The company met or surpassed earnings estimates with 2 EPS beats over the last 4 quarters. Meanwhile, Celularity operates with a trailing twelve-month EPS of -$2.52. Its next earnings date is scheduled for November 13, 2026.

This page is an AI-written research summary of Celularity Inc. (CELU). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CELU income statement, CELU balance sheet, CELU key metrics, CELU chart. See the CELU stock overview for the latest quote and news.